Methods and compositions for treating cancer

Patent metadata

Field	Value
Publication number	US-10722600-B2
Application number	US-201715625934-A
Country	US
Kind code	B2
Filing date	Jun 16, 2017
Priority date	Jun 17, 2016
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

The present invention relates to the use of NS1/2 region of murine norovirus MNV or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions, for treating dysbiosis, immune system dysregulation and various disorders, as well as for enhancing mucosal integrity and stimulating IFN-induced genes.

First claim

The invention claimed is:

1. A method for treating a subject, wherein the subject has cancer and/or is receiving a therapy for cancer, the method comprising administering to said subject a therapeutically effective amount of the NS1/2 genomic region of murine norovirus (MNV) comprising a nucleotide sequence encoded by the DNA sequence of SEQ ID NO: 1 or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions.

2. The method of claim 1 , wherein the subject has a small intestinal cancer or colon cancer.

3. The method of claim 1 , comprising administering a region corresponding to the NS1/2 genomic region of murine norovirus (MNV) from a human calicivirus.

4. The method of claim 1 , wherein the NS1/2 genomic region of murine norovirus (MNV) or the corresponding region from a member of the Caliciviridae family is administered in a vector.

5. The method of claim 1 , wherein the NS1/2 genomic region of murine norovirus (MNV) or the corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions is administered within a recombinant murine norovirus (MNV) engineered to infect human cells.

6. The method of claim 1 , wherein the NS1/2 genomic region of murine norovinis (MNV) or the corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions is administered in a nanoparticle, a liposomal particle, a virion-like particle, or a recombinant bacteriophage.

7. The method of claim 1 , wherein the NS1/2 genomic region of murine norovirus (MNV) or the corresponding region from a member of the Caliciviridae family is administered as naked RNA, optionally with one or more modified bases.

8. The method of claim 1 , wherein the NS1/2 region of murine norovirus (MNV) or the corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions is administered in a bacterial or fungal host cell, optionally, selected from live bacterial cells, conditionally lethal bacterial cells, inactivated bacterial cells, killed bacterial cells, and spores.

9. The method of claim 1 , wherein administration is to a mucosal surface.

10. The method of claim 1 , wherein the subject is human.

11. A method for enhancing the effectiveness of an anti-cancer therapy in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the NS1/2 genomic region of murine norovirus (MNV) comprising a nucleotide sequence encoded by the DNA sequence of SEQ ID NO: 1 or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions.

Assignees

• Univ New York

Inventors

• Cadwell Kenneth

Classifications

• C07K14/005 Primary

  from viruses · CPC title

• C12N2770/16043

  viral genome or elements thereof as genetic vector · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K14/08

  RNA viruses · CPC title

• C12N2770/16033

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title